Search companies or stocks...
Inhibikase Therapeutics, Inc. (IKT) current market price $2.50; calculated gap vs modeled fair value is 70.18%. The dollar intrinsic value estimate is available with Tickerplace Pro.
Confidence score is based on the magnitude of the gap vs the modeled estimate.
Fair value estimate
Unlock fair valueCurrent price
$2.50
Intrinsic value for Inhibikase Therapeutics, Inc. (IKT) is estimated from cash flows, growth, reinvestment, and a risk-adjusted discount rate, then compared with the current market price.
A second lens is historical valuation: today’s multiple versus the company’s own five-year average. That comparison describes where the multiple sits relative to past ranges — it is not a buy or sell conclusion.
Market price also embeds assumptions about revenue, margins, and capital returns. Use the ratios and financials linked on this page to see the inputs behind the calculated gap.
Inhibikase Therapeutics, Inc. (IKT) current market price is $2.50, a calculated difference of 70.2% versus modeled fair value. Tickerplace Pro unlocks the dollar intrinsic value estimate. This is a model output, not a recommendation.
Intrinsic value is an estimate of what IKT shares may be worth based on fundamentals rather than today's price alone. See the valuation snapshot on this page for the latest model output. Tickerplace Pro unlocks the full dollar fair value estimate.
Tickerplace calculates IKT's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to show the calculated gap.
IKT’s calculated gap versus modeled fair value is 70.2% at a market price of $2.50. A gap is a calculated difference between price and the model estimate, not a buy or sell conclusion. Confirm with ratios and financials on the company profile.
Peers for IKT: open their calculated fair value vs price view.
